Oslo, Norway, June 6th, 2022 – AdjuTec Pharma, a privately held company developing novel antibiotic resistance breakers, is excited to announce that Indian authorities have granted our APC148 patent application. India has the highest incidence of patients infected by metallo-β-lactamase (MBL) producing bacteria. These enzymes are able to destroy nearly all antibiotics available on the market. The most serious MBL is called New-Delhi-Mutant (NDM) and was first described in India. NDM-producing bacteria are often associated with lung infections and are now spreading throughout the world. A recent NDM out-break in Portugal during the pandemic clearly emphasized the importance of developing products such as meropenem+APC148, to treat infections caused by NDM-producing pathogens (Mendez et al 2022, Microorganisms).
Bjørn Klem, AdjuTec Pharma CEO, comments “The patent in India is very important for Adjutec as it covers a large territory that has the highest incidence of MBL-producing pathogens. Together with APC148 patents previously approved in US, Europe and China, Adjutec patents now cover the most important global markets.”
Full PR available here